Wire · opportunities
INO: VOCERYQ wins FDA approval to reduce surgery frequency in adults with RRP
◆ Sectors
Medtech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
VOCERYQ, developed by Inovio Pharmaceuticals, has gained FDA Accelerated Approval to reduce surgery frequency in adults suffering from recurrent respiratory papillomatosis (RRP), with 27% of patients requiring no surgery in the year following treatment.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You can now build offerings around VOCERYQ's FDA-approved approach to reduce surgeries for RRP patients in the US. This approval opens a new market entry point for Medtech startups targeting respiratory conditions.
◆ Coverage
2 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics
Medtechfda-approvalmedtechrppregulatory-updateinovio